Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination With SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer

NCT06036745 is registered in ClinicalTrials.gov with Shanghai Minimally Invasive Surgery Center as lead sponsor.

NCT NCT06036745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06036745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination With SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer
Lead sponsor
Shanghai Minimally Invasive Surgery Center
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2022
Completion date
July 1, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer stage iiib-iiic